Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics.

Alzheimer's disease (AD), the leading cause of dementia, involves regionalized neuronal death, synaptic loss, and an accumulation of intraneuronal, neurofibrillary tangles and extracellular senile plaques. Although the initiating causes leading to AD are unknown, a number of previous studies reported the role of oxidative stress in AD brain. Postmortem analysis of AD brain showed elevated markers of oxidative stress including protein nitrotyrosine, carbonyls in proteins, lipid oxidation products, and oxidized DNA bases. In this review, we focus our attention on the role of protein oxidation and lipid peroxidation in the pathogenesis of AD. Particular attention is given to the current knowledge about the redox proteomics identification of oxidatively modified proteins in AD brain.

[1]  Stanley I. Rapoport,et al.  In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[2]  G. Spiteller,et al.  Generation of α-hydroxyaldehydic compounds in the course of lipid peroxidation , 1994 .

[3]  E. Rojas,et al.  The Ability of Amyloid β‐Protein [AβP (1–40)] to Form Ca2+ Channels Provides a Mechanism for Neuronal Death in Alzheimer's Disease , 1994 .

[4]  D. Butterfield,et al.  Enhancement of β‐Amyloid Peptide Aβ(1–40)‐Mediated Neurotoxicity by Glutamine Synthetase , 1995 .

[5]  A. Scaloni,et al.  Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. , 2005, Mass spectrometry reviews.

[6]  D. Butterfield,et al.  Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. , 2002, Journal of neurotrauma.

[7]  D. Allan Butterfield,et al.  Chapter 7 Protein Oxidation Processes in Aging Brain , 1997 .

[8]  K. Davies,et al.  4-Hydroxynonenal-modified amyloid-β peptide inhibits the proteasome: possible importance in Alzheimer’s disease* , 2000, Cellular and Molecular Life Sciences CMLS.

[9]  A. Gow,et al.  Effects of peroxynitrite‐induced protein modifications on tyrosine phosphorylation and degradation , 1996, FEBS letters.

[10]  Akihiko Takashima,et al.  Alterations in Glucose Metabolism Induce Hypothermia Leading to Tau Hyperphosphorylation through Differential Inhibition of Kinase and Phosphatase Activities: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[11]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[12]  T. Montine,et al.  Prostaglandin H2 (PGH2) accelerates formation of amyloid β1−42 oligomers , 2002, Journal of neurochemistry.

[13]  G. Gibson,et al.  Protein‐Bound Acrolein , 1999, Journal of neurochemistry.

[14]  M. B. Yim,et al.  Free radicals and disease. , 2002, Archives of biochemistry and biophysics.

[15]  A. Hofman,et al.  Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.

[16]  J. Sweatt,et al.  The Role of Mitochondrial Porins and the Permeability Transition Pore in Learning and Synaptic Plasticity* , 2002, The Journal of Biological Chemistry.

[17]  M. Mattson,et al.  4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes , 1997, Neuroscience.

[18]  S. Kish,et al.  Mitochondria in Alzheimer's disease. , 2002, International review of neurobiology.

[19]  H. Jörnvall,et al.  Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Montine,et al.  Lipid peroxidation in aging brain and Alzheimer's disease. , 2002, Free radical biology & medicine.

[21]  P. Dodd,et al.  Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease , 2004, Neurochemistry International.

[22]  A. Roses,et al.  Apolipoprotein E and the CNS Response to Injury , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  I. Alafuzoff,et al.  Glycosylation changes in Alzheimer’s disease as revealed by a proteomic approach , 2004, Neuroscience Letters.

[24]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[25]  W. Markesbery,et al.  Four-Hydroxynonenal, a Product of Lipid Peroxidation, is Increased in the Brain in Alzheimer’s Disease , 1998, Neurobiology of Aging.

[26]  T. Montine,et al.  The Lipid Peroxidation Product 4‐Hydroxynonenal Inhibits Neurite Outgrowth, Disrupts Neuronal Microtubules, and Modifies Cellular Tubulin , 1999, Journal of neurochemistry.

[27]  M. Nonaka,et al.  A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. , 1996, Gene.

[28]  J. Trojanowski,et al.  Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.

[29]  S. Scheff,et al.  Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies , 2003, Neurobiology of Aging.

[30]  J. Hardy,et al.  Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease. , 1995, American journal of medical genetics.

[31]  D. Butterfield,et al.  Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35). , 2001, Journal of the American Chemical Society.

[32]  Kelvin H. Lee,et al.  Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach. , 2005, Current opinion in molecular therapeutics.

[33]  K. Davies,et al.  Selective degradation of oxidatively modified protein substrates by the proteasome. , 2003, Biochemical and biophysical research communications.

[34]  W. Sly,et al.  Human carbonic anhydrases and carbonic anhydrase deficiencies. , 1995, Annual review of biochemistry.

[35]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase‐related protein 2, α‐enolase and heat shock cognate 71 , 2002, Journal of neurochemistry.

[36]  C. Winterbourn,et al.  Protein carbonyl measurement by enzyme-linked immunosorbent assay. , 1999, Methods in enzymology.

[37]  E. Masliah,et al.  Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. , 1996, Annals of neurology.

[38]  D. Butterfield,et al.  Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease , 2004, Brain Research.

[39]  D. Butterfield,et al.  The glial glutamate transporter, GLT‐1, is oxidatively modified by 4‐hydroxy‐2‐nonenal in the Alzheimer's disease brain: the role of Aβ1–42 , 2001, Journal of neurochemistry.

[40]  A D Roses,et al.  Apolipoprotein E and Alzheimer's Disease A Rapidly Expanding Field with Medical and Epidemiological Consequences , 1996, Annals of the New York Academy of Sciences.

[41]  P. Davies.  Challenging the cholinergic hypothesis in Alzheimer disease. , 1999, JAMA.

[42]  W. Pryor,et al.  Suggested mechanisms for the production of 4-hydroxy-2-nonenal from the autoxidation of polyunsaturated fatty acids. , 1990, Free radical biology & medicine.

[43]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[44]  R. Maccioni,et al.  Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules. , 1998, Cellular and Molecular Biology.

[45]  D. Carter.  The interaction of amyloid-beta with ApoE. , 2005, Sub-cellular biochemistry.

[46]  Kai Stühler,et al.  MALDI: more than peptide mass fingerprints. , 2004, Current opinion in molecular therapeutics.

[47]  D. Craik,et al.  Role of phosphorylation in the conformation of tau peptides implicated in Alzheimer's disease. , 2000, Biochemistry.

[48]  P. A. Peterson,et al.  β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity , 2000, The Journal of Biological Chemistry.

[49]  I. Alafuzoff,et al.  Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain , 2006, Neurobiology of Aging.

[50]  Mark A. Smith,et al.  4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.

[51]  R. Dean,et al.  Biochemistry and pathology of radical-mediated protein oxidation. , 1997, The Biochemical journal.

[52]  D. Praticò,et al.  Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[53]  J. Golenser,et al.  The Role of Superoxide Dismutation in Malaria Parasites , 1999, Inflammation.

[54]  D. Butterfield.  Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. , 2002, Free radical research.

[55]  F. Schmitt,et al.  Evidence of increased oxidative damage in subjects with mild cognitive impairment , 2005, Neurology.

[56]  A. Smith,et al.  Cell cycle markers in the hippocampus in Alzheimer’s disease , 1997, Acta Neuropathologica.

[57]  S. Younkin.  Evidence that A beta 42 is the real culprit in Alzheimer's disease. , 1995, Annals of neurology.

[58]  B Herbert,et al.  Advances in protein solubilisation for two‐dimensional electrophoresis , 1999, Electrophoresis.

[59]  L. Marnett.  DNA adducts of alpha,beta-unsaturated aldehydes and dicarbonyl compounds. , 1994, IARC scientific publications.

[60]  S. Hazen,et al.  Tyrosine Nitration Impairs Mammalian Aldolase A Activity* , 2004, Molecular & Cellular Proteomics.

[61]  S. Hoyer.  Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. , 2004, Advances in experimental medicine and biology.

[62]  D. Butterfield,et al.  Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD , 2006, Neurobiology of Aging.

[63]  D. Ferrari,et al.  Activation of microglial cells by beta-amyloid protein and interferon-gamma. , 1995, Nature.

[64]  M. Weinand,et al.  Amyloid-β Induces Chemokine Secretion and Monocyte Migration across a Human Blood-Brain Barrier Model , 1998, Molecular medicine.

[65]  L. Horrocks,et al.  Lipid Peroxides in the Free Radical Pathophysiology of Brain Diseases , 1998, Cellular and Molecular Neurobiology.

[66]  D. Butterfield,et al.  Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death , 2002, Neurobiology of Aging.

[67]  D. Butterfield,et al.  Oxidative Modification of Creatine Kinase BB in Alzheimer’s Disease Brain , 2000, Journal of neurochemistry.

[68]  M. Mattson,et al.  Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  H. Esterbauer,et al.  Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. , 1990, Methods in enzymology.

[70]  D. Butterfield,et al.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress , 2002 .

[71]  D. Butterfield,et al.  In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42) , 1999, Neurobiology of aging.

[72]  G. Spiteller,et al.  Generation of alpha-hydroxyaldehydic compounds in the course of lipid peroxidation. , 1994, Biochimica et biophysica acta.

[73]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[74]  D. Butterfield,et al.  Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment , 2006, Neuroscience Letters.

[75]  C. Oliveira,et al.  Mitochondrial Dysfunction and Reactive Oxygen Species in Excitotoxicity and Apoptosis: Implications for the Pathogenesis of Neurodegenerative Diseases , 2003, Neurochemical Research.

[76]  D. Dickson,et al.  Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies , 2003, Neurobiology of Disease.

[77]  D. Butterfield,et al.  Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress , 1999, Brain Research Bulletin.

[78]  D. Butterfield,et al.  Brain Regional Correspondence Between Alzheimer's Disease Histopathology and Biomarkers of Protein Oxidation , 1995, Journal of neurochemistry.

[79]  Xiongwei Zhu,et al.  Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron* , 2005, Journal of Biological Chemistry.

[80]  D. Butterfield,et al.  Apolipoprotein E modulates Alzheimer’s Aβ(1–42)-induced oxidative damage to synaptosomes in an allele-specific manner , 2002, Brain Research.

[81]  J. Poirier,et al.  Apolipoprotein E and Low‐Density Lipoprotein Binding and Internalization in Primary Cultures of Rat Astrocytes: Isoform‐Specific Alterations , 1996, Journal of neurochemistry.

[82]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[83]  Steven A. Johnson,et al.  Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress , 1995, Experimental Neurology.

[84]  H. Soininen,et al.  Glucose intolerance, cognitive impairment and Alzheimer's disease. , 1998, Current opinion in neurology.

[85]  T. Arendt,et al.  Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus , 2002, Acta Neuropathologica.

[86]  David S. Park,et al.  Emerging Pathogenic Role for Cyclin Dependent Kinases in Neurodegeneration , 2004, Cell cycle.

[87]  J. Bockaert,et al.  Nitric oxide, superoxide and peroxynitrite: Putative mediators of NMDA-induced cell death in cerebellar granule cells , 1993, Neuropharmacology.

[88]  M. Gagnon,et al.  Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes , 1996, Behavioural Brain Research.

[89]  P. Dawson,et al.  Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates. , 1985, The Journal of biological chemistry.

[90]  D. Holtzman,et al.  Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[91]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[92]  M. Mattson,et al.  Truncated Apolipoprotein E (ApoE) Causes Increased Intracellular Calcium and May Mediate ApoE Neurotoxicity , 1999, The Journal of Neuroscience.

[93]  Jing Zhang,et al.  Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.

[94]  T. Koji,et al.  Post‐meiotic expression of the mouse dihydropyrimidinase‐related protein 3 (DRP‐3) gene during spermiogenesis , 1998, Molecular reproduction and development.

[95]  D. Butterfield.  Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain , 2004, Brain Research.

[96]  D. Butterfield,et al.  Oxidatively Induced Structural Alteration of Glutamine Synthetase Assessed by Analysis of Spin Label Incorporation Kinetics: Relevance to Alzheimer's Disease , 1997, Journal of neurochemistry.

[97]  N. Cairns,et al.  Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. , 1999, Journal of neural transmission. Supplementum.

[98]  W. Markesbery,et al.  Quantitative Proteomic Analysis of Mitochondria from Primary Neuron Cultures Treated with Amyloid Beta Peptide , 2004, Neurochemical Research.

[99]  D. Butterfield,et al.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. , 2001, Trends in molecular medicine.

[100]  N. Wood,et al.  Genetic causes of Parkinson’s disease: UCHL-1 , 2004, Cell and Tissue Research.

[101]  G. Stenbeck.  Soluble NSF-attachment proteins. , 1998, The international journal of biochemistry & cell biology.

[102]  S. Kaech,et al.  Volatile anesthetics block actin-based motility in dendritic spines. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Gert Lubec,et al.  Limitations of current proteomics technologies. , 2005, Journal of chromatography. A.

[104]  D. Butterfield,et al.  Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[105]  Robert B. Petersen,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[106]  W. B. Stine,et al.  Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. , 1995, Experimental neurology.

[107]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[108]  B. Hyman,et al.  Multiple, diverse senile plaque–associated proteins are ligands of an apolipoprotein e receptor, the α2‐macroglobulin receptor/low‐density‐lipoprotein receptor—related protein , 1995, Annals of neurology.

[109]  P. Reddy,et al.  Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease , 2007, NeuroMolecular Medicine.

[110]  D. Butterfield,et al.  Mutations in amyloid precursor protein and presenilin‐1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid β‐peptide (1–42), H2O2 and kainic acid: implications for Alzheimer's disease , 2006, Journal of neurochemistry.

[111]  J. Pincemail,et al.  Oxidative stress in clinical situations--fact or fiction? , 1996, European journal of anaesthesiology.

[112]  Roberto Colombo,et al.  Protein carbonyl groups as biomarkers of oxidative stress. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[113]  G. Ronquist,et al.  Alzheimer amyloid β‐peptides exhibit ionophore‐like properties in human erythrocytes , 1995, European journal of clinical investigation.

[114]  E. Masliah,et al.  Synaptic and neuritic alterations during the progression of Alzheimer's disease , 1994, Neuroscience Letters.

[115]  J. Rothman,et al.  Vesicular transport between the endoplasmic reticulum and the Golgi stack requires the NEM-sensitive fusion protein , 1989, Nature.

[116]  B. Halliwell,et al.  Proteasomal dysfunction induced by 4‐hydroxy‐2,3‐trans‐nonenal, an end‐product of lipid peroxidation: a mechanism contributing to neurodegeneration? , 2002, Journal of neurochemistry.

[117]  R. Carp,et al.  Oxidative Stress and Neurodegeneration in Prion Diseases , 2001, Annals of the New York Academy of Sciences.

[118]  Visith Thongboonkerd,et al.  Proteomic identification of nitrated proteins in Alzheimer's disease brain , 2003, Journal of neurochemistry.

[119]  W. Meier-Ruge,et al.  Neurochemical enzyme changes in Alzheimer's and Pick's disease. , 1984, Archives of gerontology and geriatrics.

[120]  W. Markesbery,et al.  Decrease in Peptide Methionine Sulfoxide Reductase in Alzheimer's Disease Brain , 1999, Journal of neurochemistry.

[121]  Joseph E LeDoux,et al.  Structural plasticity and memory , 2004, Nature Reviews Neuroscience.

[122]  T. Montine,et al.  Lipoproteins and lipid peroxidation in Alzheimer's disease. , 2003, The journal of nutrition, health & aging.

[123]  E. Rojas,et al.  Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[124]  T. Montine,et al.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. , 2004, Chemistry and physics of lipids.

[125]  D. Stuehr,et al.  Dynamics of protein nitration in cells and mitochondria. , 2004, American journal of physiology. Heart and circulatory physiology.

[126]  K. Anzai,et al.  Oxidation-dependent changes in the stability and permeability of lipid bilayers. , 1999, Antioxidants & redox signaling.

[127]  R. Faull,et al.  Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process , 2001, Proteomics.

[128]  H. Tohgi,et al.  Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease , 1999, Neuroscience Letters.

[129]  D. Butterfield,et al.  Protein oxidation in the brain in Alzheimer's disease , 2001, Neuroscience.

[130]  D. Dickson,et al.  The effect of oxidative stress on accumulation of apolipoprotein E3 and E4 in a cell culture model of β-amyloid angiopathy (CAA) , 2003, Brain Research.

[131]  D. Butterfield,et al.  Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. , 2004, Brain research.

[132]  S. Younkin.  Evidence that Aβ42 is the real culprit in alzheimer's disease , 1995 .

[133]  E. Stadtman,et al.  Free radical-mediated oxidation of free amino acids and amino acid residues in proteins , 2003, Amino Acids.

[134]  D. Butterfield,et al.  Antisense directed at the Aβ region of APP decreases brain oxidative markers in aged senescence accelerated mice , 2004, Brain Research.

[135]  M. Mattson,et al.  The Lipid Peroxidation Product 4-Hydroxynonenal Impairs Glutamate and Glucose Transport and Choline Acetyltransferase Activity in NSC-19 Motor Neuron Cells , 1999, Experimental Neurology.

[136]  D. Dickson,et al.  Oxidized neprilysin in aging and Alzheimer's disease brains. , 2003, Biochemical and biophysical research communications.

[137]  David A Bennett,et al.  High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. , 2005, Clinical chemistry.

[138]  J. Pié,et al.  Apoptosis of PC12 cells by 4-hydroxy-2-nonenal is mediated through selective activation of the c-Jun N-terminal protein kinase pathway. , 2001, Chemico-biological interactions.

[139]  Margaret A. Pericak-Vance,et al.  Hypothesis: Microtubule Instability and Paired Helical Filament Formation in the Alzheimer Disease Brain Are Related to Apolipoprotein E Genotype , 1994, Experimental Neurology.

[140]  Kenneth R. Brizzee,et al.  Neuron numbers and dendritic extent in normal aging and alzheimer's disease , 1987, Neurobiology of Aging.

[141]  H. Ischiropoulos.  Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. , 1998, Archives of biochemistry and biophysics.

[142]  J. Morrow,et al.  Recent advances in the biochemistry and clinical relevance of the isoprostane pathway , 2005, Lipids.

[143]  D. Butterfield,et al.  Prevention of Hyperoxia‐Induced Alterations in Synaptosomal Membrane‐Associated Proteins by N‐tert‐Butyl‐α‐Phenylnitrone and 4‐Hydroxy‐2,2,6,6‐Tetramethylpiperidin‐1‐oxyl (Tempol) , 1996, Journal of neurochemistry.

[144]  A. Shevchenko,et al.  Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels. , 1999, Methods in molecular biology.

[145]  J. Morrow,et al.  Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. , 1992, The Journal of clinical investigation.

[146]  H. Esterbauer,et al.  Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. , 1991, Free radical biology & medicine.

[147]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. , 2002, Free radical biology & medicine.

[148]  Gabriele Siciliano,et al.  Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease , 2002, Neurobiology of Aging.

[149]  D. Butterfield,et al.  Vitamin E Prevents Alzheimer's Amyloid beta-Peptide (1-42)-Induced Neuronal Protein Oxidation and Reactive Oxygen Species Production. , 2000, Journal of Alzheimer's disease : JAD.

[150]  W. Markesbery,et al.  Acrolein is increased in Alzheimer’s disease brain and is toxic to primary hippocampal cultures , 2001, Neurobiology of Aging.

[151]  K. Davies,et al.  Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells , 2001, Cellular and Molecular Life Sciences CMLS.

[152]  D. Butterfield,et al.  Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. , 2005, Biochimica et biophysica acta.

[153]  E. Corder,et al.  The role of APOE polymorphisms in late-onset dementias , 1998, Cellular and Molecular Life Sciences CMLS.

[154]  B. Penke,et al.  Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. , 2004, Current protein & peptide science.

[155]  Jonathan D. Smith,et al.  Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.

[156]  T. Arendt.  Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity , 2003, Progress in Neurobiology.

[157]  David A. Bennett,et al.  Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer’s disease , 2004, Neurobiology of Aging.

[158]  D. Butterfield.  beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. , 1997, Chemical research in toxicology.

[159]  D. Butterfield,et al.  Oxidatively Modified GST and MRP1 in Alzheimer’s Disease Brain: Implications for Accumulation of Reactive Lipid Peroxidation Products , 2004, Neurochemical Research.

[160]  Allan I. Levey,et al.  Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases* , 2004, Journal of Biological Chemistry.

[161]  S. Arlt,et al.  Increased lipoprotein oxidation in Alzheimer's disease. , 2000, Free radical biology & medicine.

[162]  F. Vandesande,et al.  Differential expression of brain proteins in glycogen synthase kinase‐3 transgenic mice: A proteomics point of view , 2002, Proteomics.

[163]  B. Freeman,et al.  NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? , 2003, Trends in biochemical sciences.

[164]  Y. Ando,et al.  Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid , 1998, Journal of the Neurological Sciences.

[165]  M. Molloy,et al.  Membrane proteins and proteomics: Un amour impossible? , 2000, Electrophoresis.

[166]  E. Masliah,et al.  Mechanisms of synaptic dysfunction in Alzheimer's disease. , 1995, Histology and histopathology.

[167]  D. Allan Butterfield,et al.  Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease , 2006, Neurobiology of Disease.

[168]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[169]  D. Mostofsky,et al.  The role of polyunsaturated fatty acids in restoring the aging neuronal membrane , 2002, Neurobiology of Aging.

[170]  J. Benito-León,et al.  Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease , 1997, Neurology.

[171]  D. Butterfield,et al.  Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach , 2006, Neurobiology of Disease.

[172]  L. V. Van Eldik,et al.  β-Amyloid Stimulation of Inducible Nitric-oxide Synthase in Astrocytes Is Interleukin-1β- and Tumor Necrosis Factor-α (TNFα)-dependent, and Involves a TNFα Receptor-associated Factor- and NFκB-inducing Kinase-dependent Signaling Mechanism* , 2000, The Journal of Biological Chemistry.

[173]  C. Behl.  Vitamin E and other antioxidants in neuroprotection. , 1999, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[174]  J. Trojanowski,et al.  New insights into genetic and molecular mechanisms of brain degeneration in tauopathies , 2000, Journal of Chemical Neuroanatomy.

[175]  Tony Hunter,et al.  Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration , 2003, Nature.

[176]  D. Butterfield,et al.  Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease , 2001, Neurochemistry International.

[177]  D. Allan Butterfield,et al.  Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis , 2006, Neurobiology of Aging.

[178]  J. Andersen,et al.  Oxidative stress in neurodegeneration: cause or consequence? , 2004, Nature Reviews Neuroscience.

[179]  W. Markesbery,et al.  Regional Membrane Phospholipid Alterations in Alzheimer's Disease , 2004, Neurochemical Research.

[180]  G. Schellenberg,et al.  Genetic dissection of Alzheimer disease, a heterogeneous disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[181]  M. Mattson,et al.  4‐Hydroxynonenal, an Aldehydic Product of Lipid Peroxidation, Impairs Signal Transduction Associated with Muscarinic Acetylcholine and Metabotropic Glutamate Receptors: Possible Action on Gαq/11 , 1997, Journal of neurochemistry.

[182]  Jan-Gowth Chang,et al.  Proteomic Identification of Lower Apolipoprotein A-I in Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[183]  D. Butterfield,et al.  Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide (1–42) , 2002 .

[184]  D. Davies,et al.  Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes , 2003, Neurobiology of Disease.

[185]  George Perry,et al.  Differential Regulation of Glutamate Receptors in Alzheimer’s Disease , 2002, Neurosignals.

[186]  G Fischer,et al.  Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. , 2000, Molecular cell.

[187]  T. Montine,et al.  Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid* , 1998, The Journal of Biological Chemistry.

[188]  Mark A. Smith,et al.  Advanced Maillard Reaction End Products, Free Radicals, and Protein Oxidation in Alzheimer's Disease a , 1994, Annals of the New York Academy of Sciences.

[189]  A. Tsugita,et al.  Analysis of blood plasma proteins in patients with Alzheimer's disease by two‐dimensional electrophoresis, sequence homology and immunodetection , 2000, Electrophoresis.

[190]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[191]  K. Lu,et al.  Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. , 2000, Progress in cell cycle research.

[192]  J. Growdon,et al.  Evidence for a membrane defect in Alzheimer disease brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[193]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[194]  S. Arlt,et al.  Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease , 2002, Current opinion in lipidology.

[195]  J. Geddes,et al.  Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism , 1996, Molecular and chemical neuropathology.

[196]  U. Reimer,et al.  Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. , 1998, Biochemistry.

[197]  F. Kelly,et al.  Evidence for Increased oxidative Damage in Patients with Cystic Fibrosis , 1994, Pediatric Research.

[198]  M. Molloy,et al.  Proteomics: technologies and applications. , 2002, Briefings in functional genomics & proteomics.

[199]  W. Markesbery,et al.  Electrochemical Analysis of Protein Nitrotyrosine and Dityrosine in the Alzheimer Brain Indicates Region-Specific Accumulation , 1998, The Journal of Neuroscience.

[200]  D. Butterfield,et al.  Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide. , 2002, Free radical biology & medicine.

[201]  B. Halliwell,et al.  The measurement and mechanism of lipid peroxidation in biological systems. , 1990, Trends in biochemical sciences.

[202]  G. Schellenberg,et al.  Apolipoprotein E genotypes and age of onset in early‐onset familial Alzheimer's disease , 1995, Annals of neurology.

[203]  H. Ischiropoulos,et al.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association? , 2003, The Journal of clinical investigation.

[204]  Y. Christen,et al.  Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.

[205]  B. Teter,et al.  Neuroplasticity in Alzheimer's disease , 2002, Journal of neuroscience research.

[206]  J. Trojanowski,et al.  Nitration of tau protein is linked to neurodegeneration in tauopathies. , 2003, The American journal of pathology.

[207]  E. Masliah,et al.  Mechanisms of cell signaling and inflammation in Alzheimer's disease. , 2005, Current drug targets. Inflammation and allergy.

[208]  D. Butterfield,et al.  Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): Implications for proposed mechanisms of toxicity. , 2004, Journal of Alzheimer's disease : JAD.

[209]  D. Butterfield,et al.  Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid β-peptide (1–42) in a transgenic Caenorhabditis elegans model , 2003, Neurobiology of Aging.

[210]  D. Butterfield,et al.  Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration , 2003, Journal of neurochemistry.

[211]  C. Lin,et al.  The Identification and Characterization of Oxidized RNAs in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[212]  Caine W. Wong,et al.  Altered Metabolism of the Amyloid β Precursor Protein Is Associated with Mitochondrial Dysfunction in Down's Syndrome , 2002, Neuron.

[213]  D L Alkon,et al.  Soluble beta-amyloid induction of Alzheimer's phenotype for human fibroblast K+ channels. , 1994, Science.

[214]  R. Katzman.,et al.  Advances in Alzheimer's disease , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[215]  D. Butterfield,et al.  Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide 1–42 , 2002, Peptides.

[216]  J. Blass,et al.  Abnormalities of mitochondrial enzymes in Alzheimer disease , 1998, Journal of Neural Transmission.

[217]  R J Mark,et al.  Amyloid β-Peptide Impairs Glucose Transport in Hippocampal and Cortical Neurons: Involvement of Membrane Lipid Peroxidation , 1997, The Journal of Neuroscience.

[218]  V. Calabrese,et al.  Vitamin E and Neurodegenerative Disorders Associated with Oxidative Stress , 2002, Nutritional neuroscience.

[219]  G. Perry,et al.  Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells , 2003, Journal of neuroscience research.

[220]  J. Williams,et al.  Determination of carbonyl groups in oxidized proteins. , 2000, Methods in molecular biology.

[221]  Roberto Colombo,et al.  Protein carbonylation in human diseases. , 2003, Trends in molecular medicine.

[222]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[223]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[224]  D. Butterfield,et al.  The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. , 2005, Biochimica et biophysica acta.

[225]  E. Stadtman,et al.  Protein Oxidation in Aging, Disease, and Oxidative Stress* , 1997, The Journal of Biological Chemistry.

[226]  R. Mahley,et al.  Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[227]  Xiongwei Zhu,et al.  Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. , 2005, Current Alzheimer research.

[228]  J. Ma,et al.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. , 1994, Nature.

[229]  E. Niki,et al.  Dynamics of lipid peroxidation and its inhibition by antioxidants. , 1993, Biochemical Society transactions.

[230]  J. Morrow,et al.  Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.

[231]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[232]  T. Shea,et al.  Differential efficacy of lipophilic and cytosolic antioxidants on generation of reactive oxygen species by amyloid-ß. , 2001, Journal of Alzheimer's disease : JAD.